Nonhealing infection despite Th1 polarization produced by a strain of Leishmania major in C57BL/6 mice

Journal of Immunology

Volumn 174, Issue 5, 2005, Pages 2934-2941

  Anderson, Charles F ^a   Mendez, Susana ^a,b   Sacks, David L ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 13; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY BURDEN; CELLULAR IMMUNITY; CHRONICITY; CLEARANCE; CYTOKINE PRODUCTION; EAR DISEASE; EXPERIMENTAL INFECTION; INFECTION RESISTANCE; INFLAMMATION; LEISHMANIA MAJOR; LYMPH NODE; LYMPHOCYTE DEPLETION; MACROPHAGE; MOUSE; MOUSE STRAIN; MOUSE STRAIN C57BL 6; NONHEALING INFECTION; NONHUMAN; PARASITE CLEARANCE; PARASITE CONTROL; PARASITE KILLING; PARASITE SURVIVAL; PRIORITY JOURNAL; RECEPTOR BLOCKING; REINFECTION; SKIN LEISHMANIASIS; SKIN ULCER; T LYMPHOCYTE; TH1 CELL; TH2 CELL; WOUND HEALING IMPAIRMENT;

EID: 14044275712     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.5.2934     Document Type: Article

References (38)

1. Reiner, S. L., and R. M. Locksley. 1995. The regulation of immunity to Leishmania major. Annu. Rev. Immunol. 13:151.
2. Sacks, D., and N. Noben-Trauth. 2002. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2:845.
3. Belkaid, Y., S. Mendez, R. Lira, N. Kadambi, G. Milon, and D. Sacks. 2000. A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity. J. Immunol. 165:969.
4. Belkaid, Y., K. F. Hoffmann, S. Mendez, S. Kamhawi, M. C. Udey, T. A. Wynn, and D. L. Sacks. 2001. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J. Exp. Med. 194:1497.
5. + T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J. Immunol. 168:3992.
6. Belosevic, M., D. S. Finbloom, P. H. Van Der Meide, M. V. Slayter, and C. A. Nacy. 1989. Administration of monoclonal anti-IFN-γ antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major. J. Immunol. 143:266.
7. + effector cells default to the Th2 pathway in interferon-γ-deficient mice infected with Leishmania major. J. Exp. Med. 179:1367.
8. + T cell response. J. Exp. Med. 181:961.
9. Mattner, F., J. Magram, J. Ferrante, P. Launois, K. Di Padova, R. Behin, M. K. Gately, J. A. Louis, and G. Alber. 1996. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur. J. Immunol. 26:1553.
10. Ghalib, H. W., M. R. Piuvezam, Y. A. Skeiky, M. Siddig, F. A. Hashim, A. M. el-Hassan, D. M. Russo, and S. G. Reed. 1993. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J. Clin. Invest. 92:324.
11. Karp, C. L., S. H. el-Safi, T. A. Wynn, M. M. Satti, A. M. Kordofani, F. A. Hashim, M. Hag-Ali, F. A. Neva, T. B. Nutman, and D. L. Sacks. 1993. In vivo cytokine profiles in patients with kala-azar: marked elevation of both interleukin-10 and interferon-γ. J. Clin. Invest. 91:1644.
12. Kenney, R. T., D. L. Sacks, A. A. Gam, H. W. Murray, and S. Sundar. 1998. Splenic cytokine responses in Indian kala-azar before and after treatment. J. Infect. Dis. 177:815.
13. Gasim, S., A. M. Elhassan, E. A. Khalil, A. Ismail, A. M. Kadaru, A. Kharazmi, and T. G. Theander. 1998. High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis. [Published erratum appears in 1998 Clin. Exp. Immunol. 112:547.] Clin. Exp. Immunol. 111:64.
14. Gasim, S., A. M. Elhassan, E. A. Khalil, A. Ismail, A. M. Kadaru, A. Kharazmi, and T. G. Theander. 1998. High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis. [Published erratum appears in 1998 Clin. Exp. Immunol. 112:547.] Clin. Exp. Immunol. 111:64.
15. Ribeiro-de-Jesus, A., R. P. Almeida, H. Lessa, O. Bacellar, and E. M. Carvalho. 1998. Cytokine profile and pathology in human leishmaniasis. Braz. J. Med Biol. Res. 31:143.
16. Holaday, B. J., M. M. Pompeu, S. Jeronimo, M. J. Texeira, A. Sousa Ade, A. W. Vasconcelos, R. D. Pearson, J. S. Abrams, and R. M. Locksley. 1993. Potential role for interleukin-10 in the immunosuppression associated with kala azar. J. Clin. Invest. 92:2626.
17. Ismail, A., A. M. El Hassan, K. Kemp, S. Gasim, A. E. Kadaru, T. Moller, A. Kharazmi, and T. G. Theander. 1999. Immunopathology of post kala-azar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profile. J. Pathol. 189:615.
18. Gasim, S., A. M. Elhassan, A. Kharazmi, E. A. Khalil, A. Ismail, and T. G. Theander. 2000. The development of post-kala-azar dermal leishmaniasis (PKDL) is associated with acquisition of Leishmania reactivity by peripheral blood mononuclear cells (PBMC). Clin. Exp. Immunol. 119:523.
19. Ajdary, S., M. H. Alimohammadian, M. B. Eslami, K. Kemp, and A. Kharazmi. 2000. Comparison of the immune profile of nonhealing cutaneous Leishmaniasis patients with those with active lesions and those who have recovered from infection. Infect. Immun. 68:1760.
20. Louzir, H., P. C. Melby, A. Ben Salah, H. Marrakchi, K. Aoun, R. Ben Ismail, and K. Dellagi. 1998. Immunologic determinants of disease evolution in localized cutaneous leishmaniasis due to Leishmania major. J. Infect. Dis. 177:1687.
21. Akuffo, H., K. Maasho, M. Blostedt, B. Hojeberg, S. Britton, and M. Bakhiet. 1997. Leishmania aethiopica derived from diffuse leishmaniasis patients preferentially induce mRNA for interleukin-10 while those from localized leishmaniasis patients induce interferon-γ. J. Infect. Dis. 175:737.
22. Melby, P. C., F. J. Andrade-Narvaez, B. J. Darnell, G. Valencia-Pacheco, V. V. Tryon, and A. Palomo-Cetina. 1994. Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis. Infect. Immun. 62:837.
23. Kane, M. M., and D. M. Mosser. 2001. The role of IL-10 in promoting disease progression in leishmaniasis. J. Immunol. 166:1141.
24. Noben-Trauth, N., R. Lira, H. Nagase, W. E. Paul, and D. L. Sacks. 2003. The relative contribution of IL-4 receptor signaling and IL-10 to susceptibility to Leishmania major. J. Immunol. 170:5152.
25. + regulatory T cells control Leishmania major persistence and immunity. Nature 420:502.
26. Neva, F. A., D. Wyler, and T. Nash. 1979. Cutaneous leishmaniasis-a case with persistent organisms after treatment in presence of normal immune response. Am. J. Trop. Med. Hyg. 28:467.
27. Spath, G. F., and S. M. Beverley. 2001. A lipophosphoglycan-independent method for isolation of infective Leishmania metacyclic promastigotes by density gradient centrifugation. Exp. Parasitol. 99:97.
28. Lutz, M. B., N. Kukutsch, A. L. Ogilvie, S. Rossner, F. Koch, N. Romani, and G. Schuler. 1999. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 223:77.
29. Carrera, L., R. T. Gazzinelli, R. Badolato, S. Hieny, W. Muller, R. Kuhn, and D. L. Sacks. 1996. Leishmania promastigotes selectively inhibit interleukin 12 induction in bone marrow-derived macrophages from susceptible and resistant mice. J. Exp. Med. 183:515.
30. + regulatory T cells in reactivation of persistent leishmaniasis and control of concomitant immunity. J. Exp. Med. 200:201.
31. + regulatory T cells. Nat. Immunol. 4:330.
32. Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057.
33. Guizani-Tabbane, L., K. Ben-Aissa, M. Belghith, A. Sassi, and K. Dellagi. 2004. Leishmania major amastigotes induce p50/c-Rel NF-κB; transcription factor in human macrophages: involvement in cytokine synthesis. Infect. Immun. 72:2582.
34. Moore, K. W., R. de Waal Malefyt, R. L. Coffman, and A. O'Garra. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19:683.
35. Roberts, M., J. Alexander, and J. Blackwell. 1990. Genetic analysis of Leishmania mexicana infection in mice single gene Scl-2 controlled predisposition to cutaneous lesion development. J. Immunogenet. 17:89.
36. Afonso, L., and P. Scott. 1993. Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis. Infect. Immun. 61:2952.
37. Padigel, U. M., J. Alexander, and J. P. Farrell. 2003. The role of interleukin-10 in susceptibility of BALB/c mice to infection with Leishmania mexicana and Leishmania amazonensis. J. Immunol. 171:3705.
38. Jones, D. E., M. R. Ackermann, U. Wille, C. A. Hunter, and P. Scott. 2002. Early enhanced Th1 response after Leishmania amazonensis infection of C57BL/6 interleukin-10-deficient mice does not lead to resolution of infection. Infect. Immun. 70:2151.